FDG-PET study for pulmonary MAC and CPA

Phase 1

Recruiting

• Conditions: pulmonary MAC infection, chronic pulmonary aspergillosis

• Registration Number: JPRN-jRCTs071190035
• Lead Sponsor: Takazono Takahiro

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-11-15
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

(1) Patients diagnosed with pulmonary Mycobacterium avium complex (MAC) infection based on American Thoracic Society / American Society of Infectious Diseases Guideline 2017, or patients diagnosed with chronic pulmonary aspergillosis (CPA) based on the European Society of Clinical Microbiology / European Society of Medical Mycology / European Respiratory Society 2017.
(2) Patients who have not been treated with antimicrobial agents against pulmonary MAC infection or CPA .
(3) Patients who are older than 20 at the time of informed consent.
(4) Patients with written informed consent after receiving sufficient information.

Exclusion Criteria

(1) Diabetic patients with poor control (more than 200 mg/dL of fasting blood glucose level).
(2) Patients with cystic fibrosis.
(3) Patients with active respiratory infection except for pulmonary MAC infection or CPA.
(4) Patients with pulmonary MAC infection and CPA.
(5) Patients with lung cancer at the time of informed consent.
(6) Women who are currently pregnant or may be pregnant.
(7) Patient who are judged unsuitable for this study by the investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified